
Pocket Program

*Current as of Friday, October 16, 2009. Schedule subject to change.
Please see final daily schedules posted in the corridors.*

Sponsors.....	3
Advisory Committee	4
Chronological Listing of Events	5
Alphabetical Listing of Presenting Companies.....	16
Categorical Listing of Presenting Companies.....	18
Hotel Map	21
Upcoming BIO Events	22

THE 8TH ANNUAL

Bio ***Investor Forum***



BIO represents more than 1,200 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. BIO also produces the annual BIO International Convention, the world's largest gathering of the biotechnology industry, along with industry-leading innovator and partnering meetings held around the world.

Published by

Biotechnology Industry Organization
1201 Maryland Ave., SW, Suite 900
Washington DC, 20024
202-962-9200 | www.bio.org

Any portion of this material may be reproduced with attribution to BIO © 2009 by the Biotechnology Industry Organization.

Biotechnology Industry Organization

James C. Greenwood, President and Chief Executive Officer

Emerging Companies and Business Development

Alan F. Eisenberg, Executive VP, Emerging Companies & Business Development

John Craighead, PhD, Director, Investor Relations & Business Development

Jen Welch, CMP, Director, Meetings & Operations

Wesley Triplett, Director, Business Development Marketing

Bernadette Blake, Manager, Registration & Customer Service

Joe Colangelo, Manager, Business Development

Celia Economides, MPH, Manager, Investor Relations

Rena'e Grant, Manager, Partnering Programs & Investor Outreach

Amy H. Nguyen, Manager, Investor Relations & Business Development

David Thomas, CFA, Manager, Industry Research & Analysis

Sponsorship and Membership

Amy Finan, Vice President, Corporate Development & Marketing

John Sloan, Managing Director, External Relations & Development

Susanna Ling, Director, Sponsorship

Jason Rupp, Director, Membership

Elizabeth Gaskins, Manager, Membership

Beth Rosenkoetter, Manager, Sponsorship

Privacy

In accordance with its Privacy Policy, BIO does not sell or rent its customer information or usage data to third parties.

Sponsors

LEAD BANK SPONSOR

Wedbush PacGrow Life Sciences

CONFERENCE CO-HOST

Rodman & Renshaw, LLC

BIO DOUBLE HELIX SPONSOR

BioGeorgia

BIO HELIX SPONSORS

Merck & Co., Inc.
North Carolina Biotechnology Center

CONFERENCE SPONSORS

Biogen Idec
BioWorld Today
Campbell Alliance
Chubb Group of Insurance Companies
Ernst & Young
Panel Intelligence
Thomson Reuters
VWR International

CONFERENCE SUPPORTERS

BioCentury
BIOTECanada
Business Wire
MedTRACK
Oxford Finance Corporation

Advisory Committee

Benjamin R. Bowen, PhD
Rodman & Renshaw, LLC

Howard Furst, MD
Deerfield Management

John R. Leone
Paul Capital

Graeme Martin, PhD
Takeda Research Investments, Inc.

Evan McCulloch, CFA
Franklin Templeton Investments

Oleg Nodelman
Biotechnology Value Fund, LP

Heather Preston, MD
TPG Biotech

Bryan E. Roberts, PhD
Venrock

Mark Schoenebaum, MD
Deutsche Bank AG

Chris Swindle
Wedbush PacGrow Life Sciences

Paul A. Wagner, PhD, CFA
RCM Capital Management LLC

Chronological Listing of Events

*Current as of Friday, October 16, 2009. Schedule subject to change.
Please see final daily schedules posted in the corridors.*

Each corporate presentation is 25 minutes long.

*Profiles of presenting companies can be found on the
Conference CD-ROM and at <http://www.bio.org/profiles>.*



BIO is proud to be working with Panel Intelligence, Inc., formerly MedPanel, Inc., to provide leading industry experts on the therapeutic workshops. As a fully committed and capable research partner, Panel Intelligence works closely with BIO to identify objectives, recruit experts, elicit information, and synthesize results. Panel Intelligence's domain expertise, global network of experts, and proven online methods can provide due diligence on one particular company, investigate a particular space, evaluate an IPO, or identify market trends and consumer preferences.

THE 8TH ANNUAL

Bio **Investor Forum**

CHRONOLOGICAL LISTING OF EVENTS

Wednesday, October 28

8:00 AM–6:00 PM	Registration Open	California Parlor
8:00 AM–6:00 PM	Networking Lounge Open	French Parlor
8:00 AM–6:00 PM	Speaker Ready Room Open	Mendocino
9:00 AM–6:00 PM	One-on-One Partnering Desk and Internet Cafe Open	Sunset Court
10:00 AM–4:55 PM	One-on-One Partnering Times Available	2nd Floor

Wednesday, October 28

12:00 PM–1:30 PM

OPENING PLENARY LUNCHEON*

Grand Ballroom

Healthcare Reform:

Sustaining Biotech Innovation in a New World

MODERATOR: Jim Greenwood; President and CEO; Biotechnology Industry Organization, former US Representative (PA)

- PANELISTS:**
- David Bowen, PhD; Staff Director, Health Policy, Senate Health, Education; Labor and Pensions Committee
 - Michelle Easton; Partner; Tarplin, Downs and Young, LLC
 - Rick Weissenstein; Senior Vice President, Healthcare Services Analyst; Washington Research Group

President Obama's commitment to passing comprehensive health reform this year has heated up Washington in 2009. The ins and outs of health reform are complex, and this panel will provide an in-depth look at health care reform—politics, policies, and impact on the biotechnology industry. Expert panelists entrenched in the debate will discuss the current political atmosphere surrounding health care reform, what policies are being deliberated, what policies are likely to be implemented as well as examine specific issues such as biosimilars and reimbursement strategies that affect the biotech industry. Audience members will have the opportunity to pose their own questions to panelists.

**Broadcasting live from Washington, DC*

Wednesday, October 28

1:30 PM–4:55 PM	Company Presentations	Marina, Pacific Heights, Presidio, Sea Cliff, Twin Peaks North
2:00 PM–4:55 PM	Therapeutic Workshops and Business Roundtables	Twin Peaks South

Wednesday, October 28

2:00 PM–3:15 PM

THERAPEUTIC WORKSHOP

Twin Peaks South

Pipelines with Promise—A Focus on Emerging Prostate Cancer Treatments**MODERATOR:** Jim Birchenough, MD; Director, US Biotechnology Equity Research; Barclay's Capital

- PANELISTS:**
- Martin Gleave, MD, FRCSC, FACS; Chief Scientific Officer; OncoGenex Pharmaceuticals, Inc.
 - Mitchell H. Gold, MD; Chief Executive Officer; Dendreon Corporation
 - Charles J. Ryan, MD; Associate Clinical Professor of Medicine - Division of Hematology/Oncology; University of California, San Francisco
 - Howard R. Soule, PhD; Executive Vice President and Chief Science Officer; Prostate Cancer Foundation

Progress in the prostate cancer pipeline in 2009 both captured the attention of healthcare investors and drew the oncologist closer to the field. Today prostate cancer affects one in six men during their lifetimes, and despite remarkable advances in early diagnosis and in the fundamental understanding of prostate cancer biology in the last 30 years, the disease remains a leading cause of cancer death worldwide. Targeted therapies, genetic research and combination therapies have been key to driving innovation, and the prostate cancer drug market is projected to experience \$2 billion in growth through 2018. Hear from clinical-stage companies and the thought leaders in the field on new therapies in development and implications for clinical practice.

Wednesday, October 28

3:30 PM–4:45 PM

BUSINESS ROUNDTABLE

Twin Peaks South

Window Shopping—The Buyer's Perspective on Today's IPO Candidates

MODERATOR: Christopher D. Earl, PhD; Former CEO; BIO Ventures for Global Health (BVGH)

- PANELISTS:**
- J. Donald deBethizy, PhD; President and CEO; Targacept
 - Ashley Dombkowski, PhD; Managing Director; MPM Capital
 - Daniel Lyons, PhD, CFA; Equity Research Analyst; Janus Capital
 - Bryan Roberts, PhD; Partner; Venrock
 - Timothy C. Rodell, MD; President and CEO; Globelimmune, Inc.

The window for biotech initial public offerings has been virtually locked tight since 2007, when only a few quality biotech companies successfully sold shares at reasonable valuations. For many that made the leap between 2004 to 2007, the public market ride has been anything but smooth. Today a majority of these companies are in desperate need of cash infusion and contributing to the current low tolerance for risk among new issuance investors. What will it take to open an IPO window, and will this public financing opportunity resemble any windows of the past? Biotech investors and market observers agree that only the companies with late-stage products, strong clinical data and solid pharmaceutical partnerships may squeeze through, attracting only the sophisticated investors more comfortable with taking on risk. Come hear buy-side, venture investor and industry perspectives—and new definitions—for initial public offerings, an IPO window, and what is needed to bring the industry a breath of fresh air and capital.

Wednesday, October 28

5:00 PM–7:00 PM

Welcoming Reception

Garden Court

Thursday, October 29

7:00 AM–6:00 PM	Registration Open	California Parlor
7:00 AM–6:00 PM	Networking Lounge Open	French Parlor
7:00 AM–6:00 PM	Speaker Ready Room Open	Mendocino
7:00 AM–6:00 PM	One-on-One Meetings Partnering Desk and Internet Cafe	Sunset Court
7:00 AM–8:30 AM	Continental Breakfast	Sunset Court
8:00 AM–4:00 PM	Company Presentations	Marina, Pacific Heights, Presidio, Sea Cliff, Twin Peaks North
8:00 AM–4:00 PM	One-on-One Partnering Times Available	2nd Floor
8:00 AM–12:15 PM	Therapeutic Workshops and Business Roundtables	Twin Peaks South

Thursday, October 29

8:00 AM–9:15 AM

THERAPEUTIC WORKSHOP

Twin Peaks South

Predicting a Frontrunner in the Race Against Pandemic Flu

MODERATOR: John Craighead, PhD; Managing Director, Investor Relations & Business Development; Biotechnology Industry Organization

- PANELISTS:**
- Tomás Aragón, MD, DrPH; Executive Director; Center for Infectious Disease & Emergency Readiness, University of California, Berkeley
 - Penny M. Heaton, MD; Vice President and Chief Medical Officer; Novavax, Inc.
 - George Kemble, PhD; Vice President, Research & Development, Vaccines; MedImmune
 - J. Joseph Kim, PhD; Chief Executive Officer; Inovio Biomedical Corporation
 - Joseph D. Miller, PhD; Chief, Laboratory Preparedness Officer, Influenza Division; Centers for Disease Control and Prevention

The world is no stranger to flu pandemics, but the focus for influenza in 2009 has been on the emergence of a new strain, one that falls outside well-documented viral and epidemiological patterns. H1N1 reached pandemic status in less than six months, and the U.S. continues to report the largest number of cases worldwide. While a majority of the cases have been resolvable, the concern that H1N1 could intensify has drawn considerable attention to vaccine development in the biotech industry. The threat of this strain, real or hyped, underscores the importance of the government's collaboration with the pharmaceutical and biotech industries and the race to complete clinical development and scale-up manufacturing. This panel will explore the challenges presented by H1N1 and focus on companies vying to emerge as the frontrunner in flu vaccine development.

Thursday, October 29

9:30 AM–10:45 AM

BUSINESS ROUNDTABLE

Twin Peaks South

**Clinical Trials that Seal the Deal—
How to Design with Strategy in Mind**

MODERATOR: TBA

- PANELISTS:
- Keaven Anderson, PhD; Executive Director, Late Development Statistics; Merck Research Laboratories
 - Timothy Herpin, PhD; Head of US Search, Strategic Transactions Group; Bristol-Myers Squibb
 - Roger Hill, PhD, MBA; Executive Director, Licensing & Business Development; Boehringer Ingelheim
 - Joel Verter, PhD; Senior Vice President; Statistics Collaborative, Inc.

Clinical trial design is of critical importance for successful product development and marketing outcomes on the pathway to building new brands and lifesaving therapies. As clinical studies grow costlier and more complex from a regulatory perspective, biotech companies are faced with the challenge of designing studies that achieve solid clinical and long-term commercial objectives within a truncated spending model. Companies need to choose the right indication and consider the best route of drug development to yield the highest success rate and value. Some companies are electing to only perform development through Phase 2. Another area of current focus is adaptive clinical trial design, which allows for shorter and less expensive clinical studies, but has the potential to produce more complex statistics. This panel will explore how to undertake meaningful clinical trials design with a broader objective in mind—to attract big pharma or biotech as a future business development partner. Panelists will discuss traditional design versus adaptive design issues, and how short-sighted and rational clinical trial practices can limit partnering opportunities or drive more appealing transactions.

Thursday, October 29

11:00 AM–12:15 PM

THERAPEUTIC WORKSHOP

Twin Peaks South

Making it Personal—Transforming Patient Outcomes and Narrowing Development Risk

MODERATOR: Ronald W. Lennox, DPhil; Partner; CHL Medical Partners

- PANELISTS:
- Alessandra Cesano, MD, PhD; Chief Medical Officer; Nodality, Inc.
 - Todd Klingler, PhD; Vice President of Information Sciences; XDX Expression Diagnostics
 - Pamela Munster, MD; Associate Professor of Medicine, Division of Hematology/Oncology; University of California, San Francisco
 - Ellen E. Sheets, MD, Chief Medical Officer, Predictive Biosciences

Insights into the molecular and genetic basis of disease are driving new product opportunities and categories in patient diagnosis, prognosis, monitoring and treatment. Promising improved treatment outcomes and treatment tailored to genetic etiology and disease pathology, the field of molecular diagnostics and genomics offers the opportunity to invest in new products with reduced development costs, faster product cycles and more quickly realized returns. Perhaps even more exciting, product innovation in personalized medicine may play a role in optimizing and expediting the development of targeted therapies for many cancers and other conditions among validated patient populations. Focusing on these new markets, industry executives and investors will guide a discussion of some of the most compelling new therapeutic products, technologies and applications in personalized medicine.

Thursday, October 29

12:00 PM - 1:30 PM	Box Lunches Available	Sunset Court
12:30 PM - 3:00 PM	Therapeutic Workshops and Business Roundtables	Twin Peaks South

Thursday, October 29

12:30 PM–1:45 PM

BUSINESS ROUNDTABLE

Twin Peaks South

Testing the Water—Can New Deal Structures De-Risk M&A?

MODERATOR: Jeffrey R. Greene; Global Transaction Advisory Leader, Life Sciences; Ernst & Young LLP

- PANELISTS:**
- Paul J. Hastings; President and CEO; OncoMed
 - Craig C. Parker; CFO and Senior VP, Finance and Corporate Development; Proteolix, Inc.
 - Marc Grasso, MD; Managing Director, Head of West Coast Investment Banking; Leerink Swann

The challenges posed by today's economic environment have given way to a new class of deal structures. Traditionally part of licensing agreements, option-based deals have now ventured into M&A as way for pharma and biotech to de-risk the portfolio. In addition, many recent acquisitions are with existing partners—a way to get on the inside before making the plunge. Is this trend here to stay or do tough times equal tougher terms for Biotech M&A? Are these deals net positive for biotech, pharma or both? In this panel we'll discuss these new deal structures and those that might be seen in coming months.

Thursday, October 29

2:00 PM–3:00 PM

THERAPEUTIC WORKSHOP

Twin Peaks South

Resisting the Enemy Within—Keeping Score on the War Against Autoimmune Disease

MODERATOR: Liana Moussatos, PhD; Senior Healthcare Research Analyst; Wedbush PacGrow Life Sciences

- PANELISTS:**
- C. Garrison Fathman, MD; Chief Division of Immunology and Rheumatology; Stanford University School of Medicine
 - John A. Hardin, MD; Chief Scientific Officer; Arthritis Foundation
 - Sandra C. Raymond; President and CEO; Lupus Foundation of America
 - Alan M. Solinger, MD, FACP, FACR; Vice President of Clinical Immunology; XOMA
 - Peter A. Thompson, MD, FACP; President & CEO; Trubion Pharmaceuticals

Arthritis, lupus, gout and other debilitating inflammatory conditions are chronic autoimmune illnesses characterized by an immune system that has become misdirected. An estimated 43 million people in the United States alone develop autoimmune rheumatic conditions. By 2020, there will be 60 million diagnosed. Unfortunately, many patients do not fully respond to available treatments and those treatments that are available are known to cause further complications, such as PML. With the discovery of new molecular targets and pathways, companies are advancing new classes of medicines for autoimmune inflammatory diseases, including oral kinase inhibitors in RA and monoclonal antibodies in lupus. The current pipeline may hold the answer for millions of patients. Companies with late-stage compounds for arthritis and inflammatory diseases, key opinion leaders and advocates will provide insights on experimental new autoimmune therapies, clinical need and application and the development landscape.

Thursday, October 29

4:00 PM–5:15 PM

CLOSING PLENARY SESSION

Twin Peaks North/South

The Last Word: Forecasting 2010

MODERATOR: George Milstein; Managing Director, Healthcare Mergers and Acquisitions; Wedbush PacGrow Life Sciences

- PANELISTS:**
- Michelle S. Doig; Principal, Corporate Finance; Abingworth
 - Howard Furst, MD; Partner; Deerfield Management
 - Evan McCulloch, CFA; Vice President and Portfolio Manager; Franklin Templeton Investments
 - Oleg Nodelman; Portfolio Manager; Biotechnology Value Fund, LP
 - Deepa Pakianathan, PhD; Partner; Delphi Ventures

The prospects for an IPO window, in addition to new investment models, creative big pharma pipeline deals, government research funding and healthcare reform—are key catalysts for the growth of the biotech industry in 2010. What do we need to offset investor reticence around drug development risk and to reinvigorate public capital access and capital inflows into the biotech sector again? Which companies are likely to benefit? Is it possible to anticipate which business models or strategies will be out of favor? This year's BIO Investor Forum closing panel will focus on upcoming milestones, events in the industry that might signal, despite a challenging environment, the biotechnology industry is poised for a new phase of growth.

Thursday, October 29

5:30 PM - 6:30 PM Cocktail Reception

Sunset Court

Presenting Companies

Alphabetical Listing of Presenting Companies.....	16
Categorical Listing of Presenting Companies.....	18

*Current as of Friday, October 16, 2009.
Please see final daily schedules posted in the corridors.*

Each corporate presentation is 25 minutes long.

*Profiles of presenting companies can be found on the
Conference CD-ROM and at <http://www.bio.org/profiles>.*

THE 8TH ANNUAL

Bio **Investor Forum**

ALPHABETICAL LISTING PRESENTING COMPANIES

<i>Company Name</i>	<i>Ticker</i>	<i>Therapeutic Category</i>	<i>State/Country</i>
Acologix, Inc.		Musculoskeletal	CA – USA
Advanced Life Sciences, Inc.	ADLS	Biodefense	IL – USA
Advaxis Inc.	ADXS	Vaccines	NJ – USA
ADVENTRX Pharmaceuticals, Inc.	ANX	Oncology	CA – USA
Affectis Pharmaceuticals AG		CNS	Germany
Alchemia Ltd.	ACL	Drug Discovery	Australia
Allon Therapeutics Inc.	NPC	CNS	Canada
Amira Pharmaceuticals, Inc.		Drug Discovery	CA – USA
Anadys Pharmaceuticals Inc.	ANDS	Infectious Disease	CA – USA
Aradigm Corp.	ARDM	Drug Delivery	CA – USA
Ascent Therapeutics, Inc.		Biopharmaceuticals	MA – USA
Athersys Inc.	ATHX	Gene/Cell Therapy	OH – USA
Bayhill Therapeutics, Inc.		Autoimmune	CA – USA
BioSante Pharmaceuticals Inc.	BPAX	Hormone Therapy	IL – USA
Biotec Pharmacon ASA	BIOTEC	Immunology	Norway
BrainCells, Inc.		CNS	CA – USA
Calistoga Pharmaceuticals, Inc.		Immunology	WA – USA
Catalyst Biosciences, Inc.		Biopharmaceuticals	CA – USA
Cell Therapeutics Inc.	CTIC	Drug Development	WA – USA
Celladon Corporation		Cardiovascular	CA – USA
Ceregene, Inc.		Gene/Cell Therapy	CA – USA
Chimerix, Inc.		Vaccines	NC – USA
Cipher Pharmaceuticals, Inc.	DND	Drug Delivery	Canada
Cleveland BioLabs Inc.	CBLI	Biodefense	NY – USA
CoLucid Pharmaceuticals, Inc.		CNS	NC – USA
Complete Genomics, Inc.		Pharmacogenetics	CA – USA
Cosmid Corp LLC		Genetic Disorders	CO – USA
CureDuchenne		Musculoskeletal	CA – USA
Curis, Inc.	CRIS	Oncology	MA – USA
Cyclacel Pharmaceuticals Inc.	CYCC	Oncology	NJ – USA
Cylene Pharmaceuticals, Inc.		Hematology	CA – USA
EGEN, Inc.		Drug Delivery	AL – USA
Epeius Biotechnologies, Inc.		Biopharmaceuticals	CA – USA
Epilepsy Therapy Project		CNS	VA – USA
Essentialis, Inc.		Cardiovascular	CA – USA
ExonHit Therapeutics SA	ALEHT	CNS	France
Fast Forward, LLC		CNS	NY – USA
GenSpera, Inc.	GNSZ	Drug Development	TX – USA
GenVec Inc.	GNVC	Biopharmaceuticals	MD – USA
Globelmmune, Inc.		Gastroenterology	CO – USA
Hana Biosciences, Inc.	HNAB	Oncology	CA – USA
Icagen, Inc.	ICGN	CNS	NC – USA
Idera Pharmaceuticals Inc.	IDRA	Autoimmune	MA – USA
ImmunoVaccine Inc.	IMV	Infectious Disease	Canada
ImmuPharma PLC	IMM	Autoimmune	UK
Inimex Pharmaceuticals Inc.		Immunology	Canada
Inotek Pharmaceuticals Corp.		Ophthalmic	MA – USA
Inovio Biomedical Corporation	INO	Infectious Disease	CA – USA
Intarcia Therapeutics, Inc.		Drug Delivery	CA – USA
Intrexon Corporation		Biopharmaceuticals	VA – USA
KAI Pharmaceuticals, Inc.		Cardiovascular	CA – USA
KaloBios Pharmaceuticals, Inc.		Inflammation	CA – USA
Life Sciences Analytics, Inc. (MedTRACK)		Other	PA – USA
LigoCyte Pharmaceuticals, Inc.		Vaccines	MT – USA
Locus Pharmaceuticals, Inc.		Drug Discovery	PA – USA
Logical Therapeutics, Inc.		Musculoskeletal	MA – USA
Lupus Foundation of America		Autoimmune	DC – USA
Macrogenics, Inc.		Autoimmune	MD – USA
MDA Venture Philanthropy		Musculoskeletal	AZ – USA
mdRNA, Inc.	MRNA	Cardiovascular	WA – USA
Medicago, Inc.	MDG	Immunology	Canada

ALPHABETICAL LISTING PRESENTING COMPANIES

<i>Company Name</i>	<i>Ticker</i>	<i>Therapeutic Category</i>	<i>State/Country</i>
MethylGene Inc.	MYG	Hematology	Canada
Micromet, Inc.	MITI	Oncology	MD – USA
NeurAxon, Inc.		CNS	Canada
Newron Pharmaceuticals SpA	NWRN	CNS	Italy
NovaBay Pharmaceuticals Inc.	NBY	Infectious Disease	CA – USA
Novalar Pharmaceuticals, Inc.		Dental	CA – USA
Novavax, Inc.	NVAX	Drug Development	MD – USA
Novelos Therapeutics Inc.	NVLT	Biopharmaceuticals	MA – USA
Nuon Therapeutics, Inc.		Autoimmune	CA – USA
NuPathe Inc.		CNS	PA – USA
Oncolytics Biotech Inc.	ONCY	Drug Development	Canada
OncoMed Pharmaceuticals, Inc.		Oncology	CA – USA
Osteologix Inc.	OLGX	Musculoskeletal	VA – USA
Palatin Technologies, Inc.	PTN	Biopharmaceuticals	NJ – USA
Peptimmune, Inc.		Immunology	MA – USA
Plexxikon Inc.		Drug Discovery	CA – USA
Portola Pharmaceuticals, Inc.		Cardiovascular	CA – USA
Presidio Pharmaceuticals, Inc.		Infectious Disease	CA – USA
Profectus BioSciences, Inc.		Infectious Disease	MD – USA
Provectus Pharmaceuticals, Inc.	PVCT	Oncology	TN – USA
PTC Therapeutics, Inc.		Genetic Disorders	NJ – USA
QuatRx Pharmaceuticals		Drug Development	MI – USA
Raptor Pharmaceutical Corp.	RPTP	Biopharmaceuticals	CA – USA
Reata Pharmaceuticals, Inc.		CNS	TX – USA
Regado Biosciences, Inc.		Cardiovascular	NJ – USA
RegeneRX Biopharmaceuticals Inc.	RGN	Cardiovascular	MD – USA
Regulus Therapeutics, Inc.		Cardiovascular	CA – USA
Resolvix Pharmaceuticals, Inc.		Inflammation	MA – USA
Rexahn Pharmaceuticals, Inc.	RNN	CNS	MD – USA
SARcode Corporation		Immunology	CA – USA
Somaxon Pharmaceuticals Inc.	SOMX	CNS	CA – USA
Stromedix, Inc.		Drug Development	MA – USA
SuperGen, Inc.	SUPG	Drug Development	CA – USA
Taligen Therapeutics, Inc.		Immunology	MA – USA
Targacept, Inc.	TRGT	Biopharmaceuticals	NC – USA
The Leukemia and Lymphoma Society		Hematology	NY – USA
Theraclone Sciences, Inc.		Infectious Disease	WA – USA
Tobira Therapeutics, Inc.		Drug Development	NJ – USA
Topica Pharmaceuticals, Inc.		Infectious Disease	CA – USA
Transdel Pharmaceuticals, Inc.		Drug Delivery	CA – USA
Tranzyme Pharma, Inc.		Chemistry	NC – USA
Trubion Pharmaceuticals, Inc.	TRBN	Autoimmune	WA – USA
VirtualScopics Inc.	VSCP	Cardiovascular	NY – USA
VLST Corporation, Inc.		Autoimmune	WA – USA
WaferGen Bio-Systems Inc.	WGBS	Diagnostics	CA – USA
Willex AG	WL6	Biopharmaceuticals	Germany
ZIOPHARM Oncology Inc.	ZIOP	Drug Development	NY – USA

CATEGORICAL LISTING PRESENTING COMPANIES

Autoimmune

Bayhill Therapeutics, Inc.	Private	CA – USA
Idera Pharmaceuticals Inc. (IDRA)	Public	MA – USA
ImmuPharma PLC (IMM)	Public	UK
Lupus Foundation of America	PAG/NP	DC – USA
Macrogenics, Inc.	Private	MD – USA
Nuon Therapeutics, Inc.	Private	CA – USA
Trubion Pharmaceuticals, Inc. (TRBN)	Public	WA – USA
VLST Corporation, Inc.	Private	WA – USA

Biodefense

Advanced Life Sciences, Inc. (ADLS)	Public	IL – USA
Cleveland BioLabs Inc. (CBLI)	Public	NY – USA

Biopharmaceuticals

Ascent Therapeutics, Inc.	Private	MA – USA
Catalyst Biosciences, Inc.	Private	CA – USA
Epeius Biotechnologies, Inc.	Private	CA – USA
GenVec Inc. (GNVC)	Public	MD – USA
Intrexon Corporation	Private	VA – USA
Novelos Therapeutics Inc. (NVLТ)	Public	MA – USA
Palatin Technologies, Inc. (PTN)	Public	NJ – USA
Raptor Pharmaceutical Corp. (RPTP)	Public	CA – USA
Targacept, Inc. (TRGT)	Public	NC – USA
Willex AG (WL6)	Public	Germany

Cardiovascular

Celladon Corporation	Private	CA – USA
Essentialis, Inc.	Private	CA – USA
KAI Pharmaceuticals, Inc.	Private	CA – USA
mdRNA, Inc. (MRNA)	Public	WA – USA
Portola Pharmaceuticals, Inc.	Private	CA – USA
Regado Biosciences, Inc.	Private	NJ – USA
RegeneRX Biopharmaceuticals Inc. (RGN)	Public	MD – USA
Regulus Therapeutics, Inc.	Private	CA – USA
VirtualScopics Inc. (VSCP)	Public	NY – USA

Chemistry

Tranzyme Pharma, Inc.	Private	NC – USA
-----------------------	---------	----------

CNS

Affectis Pharmaceuticals AG	Private	Germany
Allon Therapeutics Inc. (NPC)	Public	Canada
BrainCells, Inc.	Private	CA – USA
CoLucid Pharmaceuticals, Inc.	Private	NC – USA
Epilepsy Therapy Project	PAG/NP	VA – USA
ExonHit Therapeutics SA (ALEHT)	Public	France
Fast Forward, LLC	PAG/NP	NY – USA
Icagen, Inc. (ICGN)	Public	NC – USA
NeurAxon, Inc.	Private	Canada
Newron Pharmaceuticals SpA (NWRN)	Public	Italy
NuPathe Inc.	Private	PA – USA
Reata Pharmaceuticals, Inc.	Private	TX – USA
Rexahn Pharmaceuticals, Inc. (RNN)	Public	MD – USA
Somaxon Pharmaceuticals Inc. (SOMX)	Public	CA – USA

**Patient Advocacy Group/Non-Profit*

Dental

Novalar Pharmaceuticals, Inc.	Private	CA – USA
-------------------------------	---------	----------

Diagnostics

WaferGen Bio-Systems Inc. (WGBS)	Public	CA – USA
----------------------------------	--------	----------

Drug Delivery

Aradigm Corp. (ARDM)	Public	CA – USA
Cipher Pharmaceuticals, Inc. (DND)	Public	Canada
EGEN, Inc.	Private	AL – USA
Intarcia Therapeutics, Inc.	Private	CA – USA
Transdel Pharmaceuticals, Inc.	Private	CA – USA

Drug Development

Cell Therapeutics Inc. (CTIC)	Public	WA – USA
GenSpera, Inc. (GNSZ)	Public	TX – USA
Novavax, Inc. (NVAX)	Public	MD – USA
Oncolytics Biotech Inc. (ONCY)	Public	Canada
QuatRx Pharmaceuticals	Private	MI – USA
Stromedix, Inc.	Private	MA – USA
SuperGen, Inc. (SUPG)	Public	CA – USA
Tobira Therapeutics, Inc.	Private	NJ – USA
ZIOPHARM Oncology Inc. (ZIOP)	Public	NY – USA

Drug Discovery

Alchemia Ltd. (ACL)	Public	Australia
Amira Pharmaceuticals, Inc.	Private	CA – USA
Locus Pharmaceuticals, Inc.	Private	PA – USA
Plexxikon Inc.	Private	CA – USA

Gastroenterology

Globelmmune, Inc.	Private	CO – USA
-------------------	---------	----------

Gene/Cell Therapy

Athersys Inc. (ATHX)	Public	OH – USA
Ceregene, Inc.	Private	CA – USA

Genetic Disorders

Cosmid Corp LLC	Private	CO – USA
PTC Therapeutics, Inc.	Private	NJ – USA

Hematology

Cylene Pharmaceuticals, Inc.	Private	CA – USA
MethylGene Inc. (MYG)	Public	Canada
The Leukemia and Lymphoma Society	Private	NY – USA

Hormone Therapy

BioSante Pharmaceuticals Inc. (BPAX)	Public	IL – USA
--------------------------------------	--------	----------

**Patient Advocacy Group/Non-Profit*

CATEGORICAL LISTING PRESENTING COMPANIES

Immunology

Biotec Pharmacon ASA (BIOTEC)	Public	Norway
Calistoga Pharmaceuticals, Inc.	Private	WA – USA
Inimex Pharmaceuticals Inc.	Private	Canada
Medicago, Inc. (MDG)	Public	Canada
Peptimmune, Inc.	Private	MA – USA
SARcode Corporation	Private	CA – USA
Taligen Therapeutics, Inc.	Private	MA – USA

Infectious Disease

Anadys Pharmaceuticals Inc. (ANDS)	Public	CA – USA
ImmunoVaccine Inc. (IMV)	Public	Canada
NovaBay Pharmaceuticals Inc. (NBY)	Public	CA – USA
Presidio Pharmaceuticals, Inc.	Private	CA – USA
Profectus BioSciences, Inc.	Private	MD – USA
Theraclone Sciences, Inc.	Private	WA – USA
Topica Pharmaceuticals, Inc.	Private	CA – USA

Inflammation

KaloBios Pharmaceuticals, Inc.	Private	CA – USA
Resolvix Pharmaceuticals, Inc.	Private	MA – USA

Musculoskeletal

Acologix, Inc.	Private	CA – USA
CureDuchenne	PAG/NP	CA – USA
Logical Therapeutics, Inc.	Private	MA – USA
MDA Venture Philanthropy	PAG/NP	AZ – USA
Osteologix Inc. (OLGX)	Public	VA – USA

Oncology

ADVENTRX Pharmaceuticals, Inc. (ANX)	Public	CA – USA
Curis, Inc. (CRIS)	Public	MA – USA
Cyclacel Pharmaceuticals Inc. (CYCC)	Public	NJ – USA
Hana Biosciences, Inc. (HNAB)	Public	CA – USA
Micromet, Inc. (MITI)	Public	MD – USA
OncoMed Pharmaceuticals, Inc.	Private	CA – USA
Provectus Pharmaceuticals, Inc. (PVCT)	Public	TN – USA

Ophthalmic

Inotek Pharmaceuticals Corp.	Private	MA – USA
------------------------------	---------	----------

Other

Life Sciences Analytics, Inc. (MedTRACK)	Private	PA – USA
--	---------	----------

Pharmacogenetics

Complete Genomics, Inc.	Private	CA – USA
-------------------------	---------	----------


Vaccines

Advaxis Inc. (ADXS)	Public	NJ – USA
Chimerix, Inc.	Private	NC – USA
LigoCyte Pharmaceuticals, Inc.	Private	MT – USA

**Patient Advocacy Group/Non-Profit*

Hotel Map

Palace Hotel Second Floor



UPCOMING BIO EVENTS

Advanced Business Development Course

October 30–November 1, 2009 | Vienna, Austria

BiO-Europe International Partnering Conference

November 2–4, 2009 | Vienna, Austria

Pacific Rim Summit on Industrial Biotechnology and Bioenergy

November 8–11, 2009 | Honolulu, HI

7th Annual BiO Asia International Partnering Conference

January 25–26, 2010 | Tokyo, Japan

12th Annual BiO CEO & Investor Conference

February 8–9, 2010 | New York, NY

BIO-Windhover and Windhover Pharmaceutical Outlook (PSO)

February 23–25, 2010 | New York, NY

BiO-Europe Spring

March 8–9, 2010 | Barcelona, Spain

3rd Annual BiO National Venture Conference

April 6–7, 2010 | Boston, MA

BIO-LES Advanced Business Development Course

April 8–10, 2010 | Boston, MA

BIO Executive Presentation Workshop

May 2, 2010 | Chicago, IL

Partnering for Global Health 2010

(with access to The Business Forum™)

May 3, 2010 | Chicago, IL

The Business Forum™ at the BiO International Convention

May 3–6, 2010 | Chicago, IL

11th Annual BioEquity Europe

May 19–20, 2010 | Zurich, Switzerland

The World Congress on Industrial Biotechnology and Bioprocessing

June 27–30, 2010 | Washington, DC

BiO India International Partnering Conference

September 21–22, 2010 | Hyderabad, India

9th Annual BIO Investor Forum

October 6–7, 2010 | San Francisco, CA

BiO-Europe International Partnering Conference

November 15–17, 2010 | Munich, Germany

